GH
Guardant Health, Inc.
GH lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
GH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GH PE Valuation
GH has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
GH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.69 | -$0.48 |
| Q2 2026 | -$3.50 | -$0.15 |
| Q1 2026 | -$3.40 | -$0.01 |
| Q4 2025 | -$3.32 | +$0.24 |
| Q3 2025 | -$3.21 | +$1.03 |
| Q2 2025 | -$3.35 | +$0.74 |
| Q1 2025 | -$3.39 | +$0.53 |
| Q4 2024 | -$3.56 | +$0.72 |
GH has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $361M | +36% |
| Q2 2026 | $335M | +44% |
| Q1 2026 | $301.7M | +48% |
| Q4 2025 | $281.3M | +39% |
| Q3 2025 | $265.2M | +39% |
| Q2 2025 | $232.1M | +31% |
| Q1 2025 | $203.5M | +21% |
| Q4 2024 | $201.8M | +30% |
GH's revenue has grown year over year every quarter since late 2020: $361M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +0.5 points |
| Q2 2026 | -39% | +7.3 points |
| Q1 2026 | -40% | +14 points |
| Q4 2025 | -43% | +20 points |
| Q3 2025 | -37% | +24 points |
| Q2 2025 | -46% | +11 points |
| Q1 2025 | -55% | +4.6 points |
| Q4 2024 | -62% | +65 points |
GH's operating margin was −37% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over GH on profitability, with a higher operating margin.
GH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.2M | +$8.6M |
| Q2 2026 | -$69.5M | -$3.6M |
| Q1 2026 | -$71.2M | -$4.1M |
| Q4 2025 | -$54.2M | +$29.2M |
| Q3 2025 | -$45.8M | +$9.5M |
| Q2 2025 | -$65.9M | +$33.1M |
| Q1 2025 | -$67.1M | -$29.9M |
| Q4 2024 | -$83.4M | -$583K |
GH has burned cash in almost every quarter: −$232M over the past year, against −$262M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GH on cash generation, producing positive trailing cash flow while its opponent burns cash.
GH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | +7.7% | +9.6M shares |
| 3 years | +14% | +16.7M shares |
| 5 years | +33% | +33M shares |
| Available history | +48% | +43.8M shares |
GH has 134M diluted shares, up 7.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $45M |
| Q4 2019 | — |
GH hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GH Net Leverage
GH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.5 | Neutral |
| Stochastic | 45.3 | Neutral |
GH's weekly RSI is 52 (neutral) and its Stochastic is 45 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GH PE vs Healthcare Sector
GH has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $166.8 | 7.2% below |
| 20 week MA | $164.2 | 5.7% below |
| 50 week MA | $128.2 | 21% above |
| 100 week MA | $90.8 | 71% above |
| 200 week MA | $59.1 | 162% above |
GH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $133.8 | +70% |
| 2021 | $133.8 | $97.5 | -27% |
| 2022 | $97.5 | $27.9 | -71% |
| 2023 | $27.9 | $27.1 | -3% |
| 2024 | $27.1 | $30.4 | +13% |
| 2025 | $30.4 | $103.0 | +238% |
| 2026 YTD | $103.0 | $154.9 | +50% |
GH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.